Depression

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Meta-analysis reveals benefit of anti-inflammatory treatment for depression and anhedonia in individuals with inflammatory phenotype.

LB Pharmaceuticals initiates a phase 2 trial for LB-102, a promising treatment for bipolar depression, aiming to address unmet needs in mood disorders.

Explore how lifestyle psychiatry transforms depression treatment through nutrition, exercise, sleep, and social connections for holistic recovery and resilience.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Innovative combinations of transcranial magnetic stimulation and ketamine therapy offer new hope for treatment-resistant depression, pain, and substance use disorders.

Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study.

Explore innovative treatments for schizophrenia, depression, and dementia, focusing on new medications and holistic care approaches for better patient outcomes.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Explore updates from November 2025, including AI, drug updates, and more.

Explore the complexities of treatment-resistant depression and the vital role of advanced practice providers in enhancing patient care and outcomes.

At-home transcranial magnetic stimulation offers a safe, effective way to treat depression, enhancing access and reducing reliance on medications.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

Semaglutide shows promise in enhancing cognitive function for individuals with psychiatric disorders, particularly improving memory and overall cognitive outcomes.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

Esketamine nasal spray shows significant improvements in treatment-resistant depression, with effective dose management and minimal adverse effects in recent studies.

A phase 2 study reveals osavampator significantly reduces depression severity in adults with major depressive disorder, showing promise for treatment-resistant cases.